NIPPON-SHOKUBAI
29.2.2024 16:01:34 CET | Business Wire | Press release
NIPPON SHOKUBAI CO., LTD. (Headquarters: Osaka, Japan, President: Kazuhiro Noda, hereinafter "Nippon Shokubai")(TOKYO:4114) combined forces with Trevi Systems Inc. (Headquarters: California, USA, CEO: John Webley, hereinafter “Trevi Systems” *1) in the development of the draw solution as a key component in the forward osmosis (hereinafter “FO”) system, which is a next generation system for seawater desalination and water treatment. With $4 million grant from US Department of Energy, Trevi Systems commenced a large scale project to demonstrate the production of fresh water at a volume of 500 m3 per day from seawater using the jointly developed draw solution on the islands of Hawaii in June, 2022 (*2) and completed the data collection in September, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240216286680/en/
Figure 1 Comparison between RO system and FO system (Graphic: Business Wire)
In recent years, water shortage has become a serious problem in the world, and reverse osmosis (hereinafter “RO”) is widely used in the seawater desalination for agricultural and drinking water use and for treatment of industrial water. The RO system is a technology that involves the pressurization of seawater or wastewater over an RO membrane to remove salts (such as NaCl) and impurities. While this system enables the acquisition of high quality water, the large amount of electric power consumed by the pressurizing pump is considered an issue (Figure 1).
Meanwhile, the FO system is focused on as a means that will resolve this issue. The FO system utilizes the osmosis, which is a natural process and occurs when liquids of differing solute concentrations are separated by a semi-permeable membrane and water moves by the process of osmosis from the solution of lower concentration to that of higher concentration. In the seawater desalination, the FO system utilizes the difference in solute concentration in seawater and draw solution, and the natural osmotic pressure as a result of the draw solution on one side of a FO membrane (a semi-permeable membrane) to pull / transport fresh water from seawater into the draw solution with everything taking place under low pressure and energy conditions (Figure 1). Nippon Shokubai and Trevi Systems developed the draw solution to be separated from the recovered water using low grade thermal heat (Photo 1).
Trevi Systems is a company in the United States which was founded in 2010. Key elements of Trevi Systems’ FO system are the use of retrograde thermolytic solute draw solution and recycling of the draw solute back to the FO membrane (Figure 2). Trevi Systems conducted a pilot test to demonstrate the production of fresh water at a volume of 50 m3 per day from seawater in Middle East (the UAE) in 2016, which confirmed that the use of the FO system was able to reduce electric power consumption to about 1/3 compared to that of the RO system.
However, the improvement in the amount of water production is necessary for the widespread utilization of the FO system at full scale, and the improvement in the function of the draw solution as the key component is crucial for realizing this. Nippon Shokubai and Trevi Systems have successfully developed a draw solution with the capability of improving water production by 30% compared with the previous product. This developed draw solution was used in the demonstration pilot plant (500m3/day) operated by Trevi Systems on the islands of Hawaii (*2).
Key achievements of the project include:
- The fresh water recovery ratio from seawater exceeded 65% surpassing commercial RO systems’ capabilities.
- Electrical energy consumption is 1/3 compared with RO systems.
- Competitive Capital Costs: Demonstrated capital costs competitive with existing RO desalination systems.
Trevi Systems is committed to further expanding the NELHA plant’s capabilities, with plans to increase capacity to over 6,000m3/day at the same site, and showcasing the potential for zero liquid discharge (*3) by the use of brine and brine concentration for mineral recovery.
The FO system is under consideration to be introduced for seawater desalination in areas with high demand for water, such as the Middle East, as well as for brine concentration to achieve zero liquid discharge. Nippon Shokubai will make further efforts to improve the performance and functions of the draw solution with a view toward future expansion of the FO system.
*1: About Trevi Systems
Trevi Systems Inc. is California based company who is a pioneer in forward osmosis technology for sustainable and efficient water desalination and brine concentration. With a commitment to innovation and environmental responsibility, Trevi Systems continues to redefine the possibilities in utilizing forward osmosis and pressurized forward osmosis to deliver clean water and other resources from the most challenging wastewaters.
For more information: https://www.trevisystems.com/
*2: FO seawater desalination project in Hawaii
The FO system by Trevi Systems was adopted in the Sun Shot program by the Department of Energy, USA. An experiment will be conducted to demonstrate the desalination of seawater using the solar heat collection facility owned by the Natural Energy Laboratory of the Hawaii Authority (NELHA).
*3: zero liquid discharge (ZLD)
One of water treatment processes intended to reduce wastewater and produce clean water that is suitable for reuse. ZLD systems purify and recycle virtually all wastewater received.
The press release issued by Nippon Shokubai is here.
The press release issued by Trevi Systems is here.
About NIPPON SHOKUBAI CO., LTD.: Nippon Shokubai utilizes the unique technology to manufacture chemicals such as ethylene oxide, acrylic acids, catalysts, superabsorbent polymers. We use chemistry to make the impossible possible, and offer unprecedented solutions to the world, specifically in Environment & Energy, Electronics & Imaging and Daily Use fields. Our corporate mission is "TechnoAmenity: Providing prosperity and comfort to people and society with our unique technology".
For more information: https://www.shokubai.co.jp/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240216286680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
